Dr. Marshall P. Stagg
Claim this profileLSU Health Baton Rouge-North Clinic
Area of expertise
Lung Cancer
Marshall P. Stagg has run 9 trials for Lung Cancer. Some of their research focus areas include:
Cancer
Marshall P. Stagg has run 7 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
LSU Health Baton Rouge-North Clinic
Our Lady Of The Lake Physicians Group - Medical Oncology
Clinical Trials Marshall P. Stagg is currently running
Atezolizumab + Chemotherapy
for Neuroendocrine Carcinoma
This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting
1 award
Phase 2 & 3
10 criteria
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting
2 awards
Phase 3
32 criteria
More about Marshall P. Stagg
Clinical Trial Related
2 years of experience running clinical trials · Led 41 trials as a Principal Investigator · 13 Active Clinical Trials
Treatments Marshall P. Stagg has experience with
- Nivolumab
- Carboplatin
- Atezolizumab
- Paclitaxel
- Cisplatin
- Fluorouracil
Breakdown of trials Marshall P. Stagg has run
Lung Cancer
Cancer
Pancreatic Cancer
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marshall P. Stagg specialize in?
Marshall P. Stagg focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage I.
Is Marshall P. Stagg currently recruiting for clinical trials?
Yes, Marshall P. Stagg is currently recruiting for 13 clinical trials in Baton Rouge Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Marshall P. Stagg has studied deeply?
Yes, Marshall P. Stagg has studied treatments such as Nivolumab, Carboplatin, Atezolizumab.
What is the best way to schedule an appointment with Marshall P. Stagg?
Apply for one of the trials that Marshall P. Stagg is conducting.
What is the office address of Marshall P. Stagg?
The office of Marshall P. Stagg is located at: LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana 70805 United States. This is the address for their practice at the LSU Health Baton Rouge-North Clinic.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.